Native Cardio to Present at the Georgetown and Maryland PNP University Pitch Session
NAPLES, Fla., February 10, 2021 (Newswire.com) - Native Cardio, Inc., a cardiac medical device manufacturer located in Naples, Florida, dedicated to developing medical devices to improve the outcomes of patients suffering from acute and chronic atrial fibrillation, announced today that Joe Pergolizzi, M.D., President and Chief Executive Officer, will be presenting at the Georgetown and Maryland PNP University Pitch Session scheduled for Feb. 10, 2021. Native Cardio is one of 23 companies selected to present during the session. Dr. Pergolizzi will participate in a 20-minute question and answer session following his presentation. The presentation may be viewed by registering at https://plugandplay.zoom.us/webinar/register/WN_9Gh319B5TuOydHj8IEl5aw.
About Native Cardio, Inc.
Native Cardio, Inc. is a cardiac medical device manufacturer located in Naples, Florida. We developed a technology that addresses a critical unmet need that often manifests following cardiovascular, thoracic, and abdominal surgery. We are referring to postoperative atrial fibrillation (POAF). POAF is a highly prevalent, must-treat cardiac condition. Our patented technology utilizes a novel approach to deliver low-energy cardioversion and/or antiarrhythmic drugs directly to the atrial heart tissue. The system is cost-efficient, reduces expenditures, and offers an effective and precise treatment solution without the severe side effects often associated with current treatment options.
Native has been accepted into the prestigious Texas Medical Center Accelerator program (TMCx). One hundred and seventy (170) companies applied, but only twenty-one (21) were selected to participate in their Bootcamp round. We are one of three (3) cardiology companies selected. We have since advanced into their full cohort. A copy of the TMCx press release may be found here: https://www.tmc.edu/innovation/news/tmcx-fall-2020-cohort/.
Source: Native Cardio
Categories: Pharmaceuticals and Biotech